NTLA | Intellia Therapeutics, Inc.

Is Intellia a Buy after its early success this year?
We all know about the red-hot sectors like electric vehicles, SPAC IPOs, and cloud based software, but the real investors know that the next industry to truly take off is in biotech, specifically in genomics.
By Mike Sakuraba | 1 week ago